Citadel Advisors’s Outset Medical OM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.02M Buy
265,700
+225,200
+556% +$923K ﹤0.01% 7611
2025
Q4
$150K Buy
+40,500
New +$347K ﹤0.01% 11318
2025
Q2
Sell
-14,840
Closed -$164K 14337
2025
Q1
$164K Buy
14,840
+11,027
+289% +$131K ﹤0.01% 10728
2024
Q4
$63.5K Buy
3,813
+1,013
+36% +$12.6K ﹤0.01% 12116
2024
Q3
$28.4K Sell
2,800
-2,573
-48% -$76.5K ﹤0.01% 12481
2024
Q2
$310K Buy
5,373
+4,246
+377% +$208K ﹤0.01% 9069
2024
Q1
$37.5K Buy
1,127
+407
+57% +$20.6K ﹤0.01% 12463
2023
Q4
$58.4K Sell
720
-153
-18% -$12.4K ﹤0.01% 11623
2023
Q3
$143K Buy
873
+200
+30% +$47.2K ﹤0.01% 10439
2023
Q2
$221K Buy
673
+340
+102% +$104K ﹤0.01% 9668
2023
Q1
$92K Buy
333
+146
+78% +$53.6K ﹤0.01% 11383
2022
Q4
$72.3K Buy
+187
New +$52.7K ﹤0.01% 11662
2022
Q2
Sell
-1,420
Closed -$967K 13739
2022
Q1
$967K Sell
1,420
-173
-11% -$104K ﹤0.01% 7774
2021
Q4
$1.1M Buy
1,593
+873
+121% +$646K ﹤0.01% 7710
2021
Q3
$534K Buy
+720
New +$491K ﹤0.01% 9701

Other funds holding OM

Citadel Advisors's OM Position: Q1 2026 in Review

Citadel Advisors sold out of Outset Medical (OM) in Q1 2026, closing a stake of 18,770 shares — an estimated $76.9K sold.

Citadel Advisors first reported a position in OM in Q3 2020 and held it in 22 quarters. The position peaked at $50.4M in Q3 2021. 99 funds tracked by Wall St. Rank hold OM as of Q1 2026.

  • Citadel Advisors reported no remaining Outset Medical position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 18,770 Outset Medical shares in Q1 2026, an estimated $76.9K.
  • Citadel Advisors first reported a position in Outset Medical in Q3 2020 and held it in 22 quarters.
  • Citadel Advisors's Outset Medical position peaked at $50.4M in Q3 2021.
  • 99 funds tracked by Wall St. Rank held Outset Medical as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.